Sitemap

• 2018redirect
• 2014public
• 2014public_tableau
• 2018public
• 2014 redirect
• 2009redirect
• Home
• Sitemap
• Getting started
  • Purpose of the HRCS
    • Use of the HRCS
    • Conditions of use
    • History of the HRCS
  • General approach to coding
    • Assigning health categories
    • Assigning research activities
    • Common mistakes
  • Training
    • Trainer resources
• Health Categories
  • Blood
  • Cancer and neoplasms
  • Cardiovascular
  • Congenital disorders
  • Ear
  • Eye
  • Infection
  • Inflammatory and immune system
  • Injuries and accidents
  • Mental health
  • Metabolic and endocrine
  • Musculoskeletal
  • Neurological
  • Oral and gastrointestinal
  • Renal and urogenital
  • Reproductive health and childbirth
  • Respiratory
  • Skin
  • Stroke
  • Generic health relevance
  • Disputed aetiology and other
• Research activities
  • 1. Underpinning research
    • 1.1 Normal biological development and functioning
    • 1.2 Psychological and socioeconomic process
    • 1.3 Chemical and physical sciences
    • 1.4 Methodologies and measurements
    • 1.5 Resources and infrastructure (underpinning)
  • 2. Aetiology
    • 2.1 Biological and endogenous factors
    • 2.2 Factors relating to physical environment
    • 2.3 Psychological, social and economic factors
    • 2.4 Surveillance and distribution
    • 2.5 Research design and methodologies (aetiology)
    • 2.6 Resources and infrastructure (aetiology)
  • 3. Prevention of disease and conditions, and promotion of well-being
    • 3.1 Primary prevention interventions to modify behaviours or promote well-being
    • 3.2 Interventions to alter physical and biological environmental risks
    • 3.3 Nutrition and chemoprevention
    • 3.4 Vaccines
    • 3.5 Resources and infrastructure (prevention)
  • 4. Detection, screening and diagnosis
    • 4.1 Discovery and preclinical testing of markers and technologies
    • 4.2 Evaluation of markers and technologies
    • 4.3 Influences and impact
    • 4.4 Population screening
    • 4.5 Resources and infrastructure (detection)
  • 5. Development of treatments and therapeutic interventions
    • 5.1 Pharmaceuticals
    • 5.2 Cellular and gene therapies
    • 5.3 Medical devices
    • 5.4 Surgery
    • 5.5 Radiotherapy and other non-invasive therapies
    • 5.6 Psychological and behavioural
    • 5.7 Physical
    • 5.8 Complementary
    • 5.9 Resources and infrastructure (treatment development)
  • 6. Evaluation of treatments and therapeutic interventions
    • 6.1 Pharmaceuticals
    • 6.2 Cellular and gene therapies
    • 6.3 Medical devices
    • 6.4 Surgery
    • 6.5 Radiotherapy and other non-invasive therapies
    • 6.6 Psychological and behavioural
    • 6.7 Physical
    • 6.8 Complementary
    • 6.9 Resources and infrastructure (treatment evaluation)
  • 7. Management of diseases and conditions
    • 7.1 Individual care needs
    • 7.2 End of life care
    • 7.3 Management and decision making
    • 7.4 Resources and infrastructure (disease management)
  • 8. Health and social care services research
    • 8.1 Organisation and delivery of services
    • 8.2 Health and welfare economics
    • 8.3 Policy, ethics and research governance
    • 8.4 Research design and methodologies (health services)
    • 8.5 Resources and infrastructure (health services)
• Guidance
  • Ageing
  • Alcohol consumption
  • Animal welfare and replacing animals in research
  • Atherosclerosis
  • Biomarkers and screening
  • Cachexia in chronic diseases and chemotherapy
  • Cancer and conditions predisposing to cancer
  • Case studies, exemplars or tracer conditions
  • Cell cycle and DNA repair
  • Cerebral palsy and spina bifida
  • Cholesterol
  • Co-morbidities
  • Congenital disorders and inherited syndromes
  • Developmental biology
  • Diet, obesity and nutrition
  • Ear and hearing
  • Economic evaluation components in trials
  • Education
  • Eye and vision
  • Foetal development, pregnancy and ‘in utero’ studies
  • Immunology and the immune system
  • Infectious diseases
  • Informatics, bioinformatics and ‘big data’
  • Liver
  • Methodologies, measurements and research designs
  • Multiple diseases and categories
  • Muscle and neuromuscular junction
  • Neuropsychology
  • Nutritional and vitamin supplements
  • Pain
  • Pharmaceuticals outside the therapeutic context
  • Physical activity and exercise
  • Policy
  • Pollution, radiation and environmental hazards
  • Prevention – differentiating primary and secondary
  • Prions – studies of TSEs, BSE, CJD and prion protein
  • Pulmonary hypertension
  • Quality of life components in trials
  • Resources and infrastructure
  • Sepsis
  • Sequelae, consequences and side effects
  • Sexual health
  • Sleep and studies of sleep disorders
  • Smoking and tobacco
  • Stem cells
  • Stratified medicine, precision medicine and personalised medicine
  • Substance misuse and addiction
  • Surgical procedures
  • Systematic reviews
  • Thromboses and embolisms
  • Treatment effectiveness
  • Trials
  • Vasculitis
  • Vertigo and disorders of balance
  • Wounds and healing
• Reports
  • Analysis reports
    • UK Health Research Analysis 2022
      • Analysis 2022 – Submission Guidance
      • Analysis 2022 – Frequently Asked Questions
      • Analysis 2022 – Data Publicity Statement
      • Analysis 2022 – Qualitative submissions
    • UK Health Research Analysis 2018
      • Analysis 2018 – news and wider use
    • UK Health Research Analysis 2014
      • 2014 analysis – news and wider use
    • UK Health Research Analysis 2009/10
    • HRCS International Workshop 2009
    • From Donation to Innovation (2007)
    • UK Health Research Analysis 2004/05
  • Analysis data
  • Analysis tools
  • Additional resources
• Blog
• Contact us
• Terms and Conditions
• Data protection
• Privacy notice
• Cookies policy
• Accessibility